Latest News
From the Journals
Specialty practices hire more physician assistants and nurse practitioners
Overall, 28% of all specialty practices employed advanced practice clinicians in 2016 – a 22% increase from 2008.
Conference Coverage
Vestibular/oculomotor component of concussion warrants more attention
NEW ORLEANS – Positive findings on the Vestibular/Ocular Motor Screening (VOMS) assessment warrant referral for targeted rehabilitation using...
FDA/CDC
FDA approves Aimovig for migraine prevention
Aimovig is the first FDA-approved treatment to prevent migraines by blocking the calcitonin gene–related peptide receptor.
Conference Coverage
Ocrelizumab safety update: Encouraging rates of serious infection, malignancy
No new safety signals were seen in the latest update from studies and postmarketing surveillance of MS patients treated with ocrelizumab.
From the Journals
Americans are getting more sleep
The younger population gained the most sleep, compared with older people included in the analysis.
Conference Coverage
Myelin antibody predicts ADEM relapse
LOS ANGELES – Could results help to guide decisions on immunosuppressive treatment?
Conference Coverage
Guidance coming for mTOR inhibitors in infantile TSC
LOS ANGELES – Survey aimed to describe the wide variation in their off-label use, particularly in infants.
FDA/CDC
FDA’s Gottlieb floats ideas on Medicare drug coverage
Trump administration officials are eying office-administered drugs in crowded therapeutic categories for the switch from Medicare Part B to...
Commentary
Two more and counting: Suicide in medical trainees
Dr. Michael F. Myers offers context for the latest discussions about physician suicides and calls on the medical community to act now.
From the Journals
Poor sleep tied to suicidal behaviors in college students
Watch for specific components of sleep, such as shorter sleep duration and feeling too cold while sleeping, in at-risk college students.
From the Journals
Fremanezumab may be an effective episodic migraine treatment
The CGRP monoclonal antibody fremanezumab significantly reduced the mean number of migraine days in patients with episodic migraine.